Why Chemed Corporation (CHE) stock moved
Chemed Corporation (CHE) shares rose 1.6% to $541.92 as of October 29, 2026, a modest gain from the prior close of $533.36. BestStocks flagged the session as a major change for CHE. The move is tied to a new SEC filing. Below, we break down what changed for CHE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
SEC Filing
Chemed Corporation (CHE) filed its Q3 2026 10-Q on October 29, 2026. CHE earnings scheduled for February 24, 2027 (date not yet confirmed).
What it means for Chemed Corporation investors
For Chemed Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 1.6% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $635.00, implying +17.2% upside from $541.92. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (51/100). With earnings roughly 118 days out, the next report is the most likely near-term test of the move.
CHE price reaction
CHE last traded at $541.92, up $8.56 (+1.60%) from the previous close of $533.36. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $498.25 and $541.92, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Chemed Corporation (CHE)
The consensus analyst price target on Chemed Corporation (CHE) is $635.00, 17.2% above the recent $541.92. Over the past 90 days analysts logged 1 upgrade, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CHE line up.
The bullish case
- Wall Street's consensus price target of $635.00 implies +17.2% upside from $541.92.
- The Street's most bullish target is $650.00 (+19.9%).
- 1 analyst upgrade in the past 90 days, most recently Jefferies to Buy (2026-10-28).
- Earnings beat with positive market reaction.
- Positive 1.6% session move.
The bearish case
- The bearish case is comparatively thin on recent signals; the main risk is that the climb toward the $635.00 consensus target has to be earned, and any of the risks BestStocks tracks could weigh on the shares.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CHE
In-depth CHE event analyses
Frequently asked questions about CHE
Why did Chemed Corporation (CHE) stock move?
CHE rose 1.6% to $541.92. The move is associated with a new SEC filing.
How much did CHE stock rise?
CHE gained 1.60% ($8.56) versus the prior close of $533.36, last trading at $541.92 on 1.2× average volume.
When is Chemed Corporation's next earnings date?
CHE's next earnings report is estimated for 2027-02-24 — about 118 days away.
What is the analyst price target for CHE?
The consensus analyst price target for CHE is $635.00, about 17.2% above the current $541.92. Over the past 90 days, analysts recorded 1 upgrade, 4 maintains, and 0 downgrades.
How BestStocks tracks CHE
This page is generated automatically by BestStocks' change-detection system after a new SEC filing was detected and verified against independent data sources. It draws on 20 tracked change events for CHE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.